Faslodex and Endometrial hypertrophy - a phase IV clinical study of FDA data

Summary:

Endometrial hypertrophy is reported as a side effect among people who take Faslodex (fulvestrant), especially for people who are 40-49 old, have been taking the drug for < 1 month also take Tamoxifen Citrate, and have Neoplasm malignant.

The phase IV clinical study analyzes which people have Endometrial hypertrophy when taking Faslodex. It is created by eHealthMe based on reports of 19,135 people who have side effects when taking Faslodex from the FDA, and is updated regularly.

What is Faslodex?

Faslodex has active ingredients of fulvestrant. It is often used in breast cancer metastatic. eHealthMe is studying from 19,255 Faslodex users. Check the latest studies of Faslodex.

What is Endometrial hypertrophy?

Endometrial hypertrophy (enlargement of uterine wall from the increase in size of its cells) is found to be associated with 73 drugs and 234 conditions by eHealthMe. Check the latest studies of Endometrial hypertrophy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

19,135 people reported to have side effects when taking Faslodex.
Among them, 14 people (0.07%) have Endometrial hypertrophy.

Could Faslodex cause Endometrial hypertrophy?

Among these 14 people:

How long have people been on Faslodex when they have Endometrial hypertrophy? *

What is the age of people who have Endometrial hypertrophy when taking Faslodex? *

What are other drugs people take besides Faslodex? *

What are other side effects people have besides Endometrial hypertrophy? *

Metastases To Bone (cancer spreads to bone): 9 people, 64.29%
Metastases To Liver (cancer spreads to liver): 9 people, 64.29%
Metastases To Lung (cancer spreads to lung): 8 people, 57.14%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 8 people, 57.14%
Gums - Swollen: 8 people, 57.14%
Hepatic Lesion: 8 people, 57.14%
Discomfort: 8 people, 57.14%
Intervertebral Disc Degeneration (spinal disc degeneration): 8 people, 57.14%
Deformity (disfigurement): 8 people, 57.14%
Lung Hyperinflation (inspiration of more than normal): 8 people, 57.14%

What are the existing conditions these people have? *

Neoplasm Malignant (cancer tumour): 8 people, 57.14%
Metastases To Bone (cancer spreads to bone): 1 person, 7.14%
High Blood Pressure: 1 person, 7.14%
Conjunctivitis (pink eye): 1 person, 7.14%
Breast Cancer Stage Iv: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Faslodex and have Endometrial hypertrophy?

- Check whether Endometrial hypertrophy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Faslodex:

Faslodex (19,255 reports)

Browse all side effects of Faslodex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Endometrial hypertrophy:

Endometrial hypertrophy (73 drugs)

Browse all the conditions that are associated with Endometrial hypertrophy:

Endometrial hypertrophy (234 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fulvestrant (the active ingredients of Faslodex) and Faslodex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.